Dataset opportunity
Vesalio — 医疗影像数据集机会
Vesalio 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
68.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗影像人工智能市场 = 2025 年为 18 亿美元，复合年增长率为 35.1%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-13
FDA clears Vesalio’s latest mechanical thrombectomy device
medicaldevice-network.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
周期性
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Vesalio 持有一个独特且有价值的医疗影像数据集，该数据集源自其在卒中治疗方面的研发和临床试验运营。该集合包含专有的血管造影影像数据、CT 扫描以及相关的去标识化医疗记录，为训练和验证神经血管疾病的高效能诊断人工智能模型提供了丰富的基础。
全球医疗影像人工智能市场在 2025 年的估值为 18 亿美元，预计到 2033 年将激增至 202 亿美元，显示出高达 35.1% 的复合年增长率。[1] 尽管这些数据涉及敏感的患者信息（PHI）并受到严格的监管监督，但其稀有性和与神经病学领域的直接相关性（该领域是市场中最大的应用领域）使其成为寻求在快速增长的行业中获得竞争优势的人工智能开发者的极其宝贵的资产。[1] ⚠ 尽职调查（有价值的数据，可协商访问）：临床试验数据涉及需要去标识化的敏感患者健康信息（PHI）；专有血管造影影像数据受到严格监管；数据主要通过研发和监管批准流程生成 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据表明 Vesalio 持有一个稀有的专有数据集，详细记录了其 NeVa 取栓支架对卒中患者的端到端治疗过程。该数据结合了临床试验记录以及术前和术后的医疗影像，为诊断人工智能开发人员创建了一个独特有价值的资产。在全球医疗影像人工智能市场年增长率超过 35% 的背景下，该数据集为训练和验证预测治疗结果和优化机械取栓程序的算法提供了关键优势。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
周期性
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求异常高，这得益于医疗影像人工智能市场的激进扩张（复合年增长率为 35.1%）以及对专业数据以训练诊断工具的关键需求。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 超出已货币化数据的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Vesalio 是一个理想的目标，因为它是一家医疗器械中小企业，其核心业务是制造和销售取栓设备，由此产生的临床和影像数据是其运营的宝贵、未货币化的副产品。
- Deep Qualification80
✓ 通过 — Vesalio 是一家医疗器械公司，其取栓产品的研发和临床试验产生了一个有价值、连贯的医疗影像数据集；然而，从公开文件中无法明确获得许可这些敏感数据的具体权利。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据证实了来自 VITAL 和 CLEAR 研究的结构化临床试验数据，这对于训练人工智能模型以预测卒中干预措施的有效性至关重要。
Image collection
持有者拥有用于验证设备性能的精选术前和术后影像数据集，为开发用于卒中治疗评估的计算机视觉算法提供了理想的真实数据。
Industrial data
这些证据指向了关于机械取栓工具在实际和台架设备性能的独特时间序列数据，使得开发预测性维护或性能优化模型成为可能。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Vesalio Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market = $1.8B in 2025, CAGR 35.1% (source: Grand View Research). Investment score 68.1/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Autamarocchi — 移动遥测数据集机会
View opportunity →交通运输Lnb Shipping — 工业运营数据集机会
View opportunity →其他Planted — 监管记录数据集机会
View opportunity →